FDA Approves XELJANZ — Pfizer Laboratories Div Pfizer Inc

Pfizer’s FDA approval of XELJANZ reinforces its competitive position in the rheumatology market, expected to drive incremental sales growth as it captures share from existing biologics. This strategic move aims to bolster Pfizer’s immunology revenue streams amidst a landscape of tightening competition.